Search Result

Results for "

Notch1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (7) Autophagy (11) Bacterial (2) COX (1) Endogenous Metabolite (11) Fungal (1) HDAC (10) HIV (10) Isotope-Labeled Compounds (4) Lipoxygenase (1) Mitophagy (10) Notch (21) Organoid (3) Reactive Oxygen Species (1) SHMT (1) Small Interfering RNA (siRNA) (3) γ-secretase (5)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1985A

Notch 1 TFA	Notch	Cardiovascular Disease Cancer
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the *NOTCH* family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types ^[1].

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human Notch1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma ^[1] .

HY-RS09445

NOTCH1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
NOTCH1 Human Pre-designed siRNA Set A contains three designed siRNAs for NOTCH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NOTCH1 Human Pre-designed siRNA Set A NOTCH1 Human Pre-designed siRNA Set A

HY-RS09446

Notch1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Notch1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Notch1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Notch1 Mouse Pre-designed siRNA Set A Notch1 Mouse Pre-designed siRNA Set A

HY-RS09447

Notch1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Notch1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Notch1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Notch1 Rat Pre-designed siRNA Set A Notch1 Rat Pre-designed siRNA Set A

HY-144899

ASR-490	Notch	Cancer
ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating *Notch1* signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice ^[1].

HY-N0232

Psoralidin 4 Publications Verification	COX Lipoxygenase Notch Reactive Oxygen Species Bacterial	Cancer
Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties ^[1]. Psoralidin significantly downregulates *NOTCH1* signaling. Psoralidin also greatly induces ROS generation .

HY-N0133

Tangeretin 5+ Cited Publications Tangeritin; NSC53909; NSC618905	Notch Apoptosis	Inflammation/Immunology Cancer
Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a *Notch-1* inhibitor.

HY-15670

BMS-906024 2 Publications Verification	γ-secretase Notch	Cancer
BMS-906024 is an orally active and selective γ-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan-Notch receptors inhibitor with IC₅₀s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively. BMS-906024 demonstrates broad-spectrum antineoplastic activity ^[1] .

HY-10585A

Valproic acid sodium 30+ Cited Publications Sodium Valproate sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-10585

Valproic acid 30+ Cited Publications Dipropylacetic Acid	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-N9790

Procyanidin B2 3,3'-di-O-gallate	Notch	Others
Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate can be isolated from grape seed extract (GSE) procyanidin mix. Procyanidin B2, 3,3' -di-o-gallate target cancer stem cells (CSCs) in prostate cancer (PCa). Procyanidin B2, 3,3'-di-O-gallate targets both unsorted and sorted CSCs at lower doses. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated *Notch1* pathway ^[1].

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-134978A

(+)SHIN2	SHMT	Cancer
(+)SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor, whose target can be traced with ¹³C-serine. (+)SHIN2 increases survival in NOTCH1-driven mouse primary acute lymphoblastic leukemia (T-ALL) in vivo with a synergistic effect with Methotrexate (HY-14519) ^[1]. (+)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0711

Carvacrol 2 Publications Verification Cymophenol	Notch Apoptosis Fungal Endogenous Metabolite Bacterial	Infection Inflammation/Immunology Cancer
Carvacrol is an orally active monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates *Notch-1, and Jagged-1, and induces apoptosis*. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations ^[1] .

HY-103539

3,5-Bis(4-nitrophenoxy)benzoic acid	γ-secretase	Metabolic Disease
3,5-Bis(4-nitrophenoxy)benzoic acid is an inhibitor of γ-secretase. 3,5-Bis(4-nitrophenoxy)benzoic acid causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25). 3,5-Bis(4-nitrophenoxy)benzoic acid, as a marker for fetal hypothyroidism, is a 3,3’-diiodothyronine sulfate (T2S) cross-reactive material in maternal serum ^[1].

HY-14174

MRK-560	γ-secretase	Neurological Disease Cancer
MRK-560 is an orally active, brain barrier-penetrating γ-Secretase inhibitor, can potently reduces Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 also decreases mutant *NOTCH1* processing by selectively inhibiting *PSEN1*. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) ^[1] .

HY-10585AS1

Valproic acid-d14 sodium Sodium Valproate-d₁₄ sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium Sodium Valproate-d₇(sodium)	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium VPA-d₄ sodium; 2-Propylpentanoic Acid-d₄ sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1 VPA-d₄-1; 2-Propylpentanoic Acid-d₄-1	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15 VPA-d₁₅; 2-Propylpentanoic Acid-d₁₅	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4 VPA-d₄; 2-Propylpentanoic Acid-d₄	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6 VPA-d₆; 2-Propylpentanoic Acid-d₆	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-12465

Z-Ile-Leu-aldehyde 2 Publications Verification Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII	Notch γ-secretase Apoptosis	Cancer
Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of γ-secretase and *notch* .

HY-12860

BMS-986115 1 Publications Verification Notch inhibitor 1	Notch	Cancer
BMS-986115 (Notch inhibitor 1) is a potent *Notch* inhibitor, with IC₅₀s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively. Used in the research of cancer ^[1].

HY-13027

DAPT Maximum Cited Publications 88 Publications Verification GSI-IX	Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of *Notch 1* signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment ^[1] .

Anti-Pancreatic Cancer Compound Library	2663 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 2663 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Protein O-Glucosyltransferase 1 EC:2.4.2.63; POGLUT1	Enzyme Substrates
Protein O-Glucosyltransferase 1 is a glucosyltransferase. Protein O-Glucosyltransferase 1 modifies *Notch* signaling by adding glucose to serine residues in Notch .

Brontictuzumab OMP 52M51; Anti-Human Notch1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0232

Psoralidin 4 Publications Verification	Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Cancer	COX Lipoxygenase Notch Reactive Oxygen Species Bacterial
Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties ^[1]. Psoralidin significantly downregulates *NOTCH1* signaling. Psoralidin also greatly induces ROS generation .

HY-N0133

Tangeretin 5+ Cited Publications Tangeritin; NSC53909; NSC618905	Structural Classification Flavonoids other families Classification of Application Fields Flavones Source classification Plants Disease Research Fields Cancer	Notch Apoptosis
Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a *Notch-1* inhibitor.

HY-10585A

Valproic acid sodium Maximum Cited Publications 33 Publications Verification Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-10585

Valproic acid Maximum Cited Publications 33 Publications Verification Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-N9790

Procyanidin B2 3,3'-di-O-gallate	Structural Classification Source classification Vitis vinifera cv. Zalema Phenols Polyphenols Plants Vitaceae	Notch
Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate can be isolated from grape seed extract (GSE) procyanidin mix. Procyanidin B2, 3,3' -di-o-gallate target cancer stem cells (CSCs) in prostate cancer (PCa). Procyanidin B2, 3,3'-di-O-gallate targets both unsorted and sorted CSCs at lower doses. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated *Notch1* pathway ^[1].

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates *Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^[1] .

HY-N0711

Carvacrol 2 Publications Verification Cymophenol	Structural Classification Monophenols Preservatives Classification of Application Fields Labiatae Phenols Plants Inflammation/Immunology Disease Research Fields Food Research	Notch Apoptosis Fungal Endogenous Metabolite Bacterial
Carvacrol is an orally active monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates *Notch-1, and Jagged-1, and induces apoptosis*. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations ^[1] .

Recombinant Proteins Recommended:

Notch-1

Species:	Human (3) Mouse (2)
Tag:	His (4) Avi (2) Fc (1)
Source:	HEK293 (4) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73742

	NOTCH1 Protein, Human (HEK293, Fc) Neurogenic locus Notch homolog protein 1; Notch 1; Motch A; mT14	Human	HEK293
	NOTCH1 protein is a receptor for the ligands JAG1, JAG2 and DLL1 and is critical for cell fate decisions. Upon ligand activation, NICD forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes in the cleavage site enhancer. NOTCH1 Protein, Human (HEK293, Fc) is the recombinant human-derived NOTCH1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of NOTCH1 Protein, Human (HEK293, Fc) is 508 a.a., with molecular weight of ~79.7 kDa.

HY-P78501

	NOTCH1 Protein, Human (HEK293, His-Avi) Notch-1; TAN1; Notch1; 9930111A19Rik; lin-12; Mis6; N1	Human	HEK293
	NOTCH1 protein is a receptor for the ligands JAG1, JAG2 and DLL1 and is critical for cell fate decisions. Upon ligand activation, NICD forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes in the cleavage site enhancer. NOTCH1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived NOTCH1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of NOTCH1 Protein, Human (HEK293, His-Avi) is 508 a.a., with molecular weight of 70-80 kDa.

HY-P71166

	NOTCH1 Protein, Mouse (HEK293, His) Neurogenic locus Notch homolog protein 1; Notch 1; Motch A; mT14	Mouse	HEK293
	NOTCH1 Protein acts as a receptor for membrane-bound ligands (JAG1, JAG2, and DLL1), determining cell fate. Upon activation, NICD forms a transcriptional activator complex, influencing differentiation, proliferation, and apoptosis. NOTCH1 negatively regulates angiogenesis, endothelial cell behavior, and impacts various developmental processes. It interacts with multiple partners, illustrating its involvement in signaling networks. NOTCH1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived NOTCH1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of NOTCH1 Protein, Mouse (HEK293, His) is 509 a.a., with molecular weight of ~70.0 kDa.

HY-P73324

	NOTCH1 Protein, Mouse (sf9, His) Neurogenic locus Notch homolog protein 1; Notch 1; Motch A; mT14	Mouse	Sf9 insect cells
	NOTCH1 Protein acts as a receptor for membrane-bound ligands (JAG1, JAG2, and DLL1), determining cell fate. Upon activation, NICD forms a transcriptional activator complex, influencing differentiation, proliferation, and apoptosis. NOTCH1 negatively regulates angiogenesis, endothelial cell behavior, and impacts various developmental processes. It interacts with multiple partners, illustrating its involvement in signaling networks. NOTCH1 Protein, Mouse (sf9, His) is the recombinant mouse-derived NOTCH1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of NOTCH1 Protein, Mouse (sf9, His) is 508 a.a., with molecular weight of ~80 kDa.

HY-P78184

	NOTCH1 Protein, Human (Biotinylated, HEK293, His-Avi) Notch-1; TAN1; Notch1; 9930111A19Rik; lin-12; Mis6; N1	Human	HEK293
	NOTCH1 protein is a receptor for the ligands JAG1, JAG2 and DLL1 and is critical for cell fate decisions. Upon ligand activation, NICD forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes in the cleavage site enhancer. NOTCH1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived NOTCH1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of NOTCH1 Protein, Human (Biotinylated, HEK293, His-Avi) is 508 a.a., with molecular weight of 70-80 kDa.

Cat. No.	Product Name	Chemical Structure

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks